John Peter Gutfreund - 15 Aug 2022 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
Director
Signature
/s/ John Peter Gutfreund
Issuer symbol
OCX
Transactions as of
15 Aug 2022
Net transactions value
+$23,250
Form type
4
Filing time
17 Aug 2022, 20:19:20 UTC
Previous filing
08 Aug 2022
Next filing
28 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OCX Common Stock, no par value Award $0 +10,000 $0.000000 10,000 15 Aug 2022 Direct F1
transaction OCX Common Stock, no par value Purchase $23,250 +25,000 $0.9300 25,000 15 Aug 2022 See footnote F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Award $0 +45,000 $0.000000 45,000 15 Aug 2022 Common Stock 45,000 $0.9700 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.
F2 The price of $0.93 per share represents a weighted average of prices ranging from $0.91 to $0.97 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 These securities are held by the minor children of the Reporting Person, and the Reporting Person has voting and dispositive control over such securities.
F4 Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.